• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.

作者信息

Deenik Wendy, van der Holt Bronno, Janssen Jeroen J W M, Chu Isabel W T, Valk Peter J M, Ossenkoppele Gert J, van der Heiden Ilse P, Sonneveld Pieter, van Schaik Ron H N, Cornelissen Jan J

出版信息

Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954.

DOI:10.1182/blood-2010-07-296954
PMID:21183698
Abstract
摘要

相似文献

1
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.多药耐药基因MDR1（ABCB1）的多态性可预测新诊断的慢性髓性白血病患者接受高剂量伊马替尼治疗时的分子耐药性。
Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954.
2
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.多药耐药基因（MDR1）多态性与慢性髓性白血病患者对标准剂量伊马替尼的主要分子反应相关。
Blood. 2008 Sep 1;112(5):2024-7. doi: 10.1182/blood-2008-03-147744. Epub 2008 Jun 4.
3
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.多药转运体基因 ABCB1 和 ABCG2 的基因型和单倍型与慢性髓性白血病患者甲磺酸伊马替尼临床反应的相关性。
Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.
4
SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.SLC22A1-ABCB1 单倍型谱预测亚洲慢性髓性白血病患者伊马替尼的药代动力学。
PLoS One. 2012;7(12):e51771. doi: 10.1371/journal.pone.0051771. Epub 2012 Dec 18.
5
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.酶和转运体多态性对慢性髓性白血病患者伊马替尼谷浓度和临床反应的影响。
Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.
6
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.采用多个候选基因的药物遗传学方法预测慢性髓性白血病对伊马替尼治疗的反应和耐药性的临床相关性。
Clin Cancer Res. 2009 Jul 15;15(14):4750-8. doi: 10.1158/1078-0432.CCR-09-0145. Epub 2009 Jul 7.
7
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.伊马替尼和达沙替尼耐药的发展：药物转运体 ABCB1、ABCC1、ABCG2、MVP 和 SLC22A1 的表达动态。
Leuk Lymphoma. 2011 Oct;52(10):1980-90. doi: 10.3109/10428194.2011.584005. Epub 2011 Jun 12.
8
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.慢性粒细胞白血病（CML）患者“获得”BCR-ABL M244V突变等位基因后对伊马替尼剂量递增的反应各异。
Blood. 2006 Oct 15;108(8):2881-2. doi: 10.1182/blood-2006-05-020859.
9
ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.ABCB1单倍型而非单个单核苷酸多态性可预测接受甲磺酸伊马替尼治疗的埃及慢性期慢性髓性白血病患者的最佳反应/治疗失败情况。
Med Oncol. 2014 Nov;31(11):279. doi: 10.1007/s12032-014-0279-y. Epub 2014 Oct 11.
10
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.伊马替尼转运体和代谢酶基因型与新诊断的慢性髓性白血病患者接受伊马替尼治疗的反应之间的关系。
Haematologica. 2013 Feb;98(2):193-200. doi: 10.3324/haematol.2012.066480. Epub 2012 Aug 8.

引用本文的文献

1
Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.基因多态性和生物标志物对慢性髓性白血病及急性髓性白血病治疗有效性和毒性的影响
J Pers Med. 2022 Sep 29;12(10):1607. doi: 10.3390/jpm12101607.
2
Pharmacogenetics of Drugs Used in the Treatment of Cancers.药物治疗癌症中的药物遗传学。
Genes (Basel). 2022 Feb 7;13(2):311. doi: 10.3390/genes13020311.
3
Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
ABCB1 基因多态性和吸烟对慢性髓性白血病易感性风险和细胞遗传学反应的影响。
Iran Biomed J. 2021 Jan;25(1):54-61. doi: 10.29252/ibj.25.1.54. Epub 2020 Aug 25.
4
Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.非受体酪氨酸激酶在血液系统恶性肿瘤中的作用及其被天然产物靶向。
Mol Cancer. 2018 Feb 19;17(1):31. doi: 10.1186/s12943-018-0788-y.
5
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.浅析 ABCB1/P-糖蛋白在慢性髓性白血病中的作用
Molecules. 2018 Jan 7;23(1):119. doi: 10.3390/molecules23010119.
6
and germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.并且种系变异可预测反应并识别出伊马替尼治疗失败风险最高的慢性粒细胞白血病患者。
Blood Adv. 2017 Jul 31;1(18):1369-1381. doi: 10.1182/bloodadvances.2017006825. eCollection 2017 Aug 8.
7
Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.靶向治疗慢性髓性白血病的药物遗传学和药物基因组学。
Mol Diagn Ther. 2017 Dec;21(6):621-631. doi: 10.1007/s40291-017-0292-x.
8
genetic variants in leukemias: current insights into treatment outcomes.白血病中的基因变异：对治疗结果的当前见解
Pharmgenomics Pers Med. 2017 May 12;10:169-181. doi: 10.2147/PGPM.S105208. eCollection 2017.
9
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
10
MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.多药耐药基因1（MDR1）多态性对中国弥漫性大B细胞淋巴瘤患者的预后有影响。
Tumour Biol. 2016 Jan;37(1):1237-44. doi: 10.1007/s13277-015-3930-0. Epub 2015 Aug 19.